Pluristem's successful stem cell trial last week on muscle injuries is an important first step for the company, says the company's CEO Zami Aberman. By using placental cells, Pluristem eliminates the ethical issues surrounding where the cells are derived, according to Aberman, who also touts his company's unique ability to manufacture 3D cells. Aberman is also bullish on Pluristem's partnership with United Therapeutics, another biotech company that has seen its shares spike in the past year.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Futures Fall on Further Trade News and 4 Other Stories to Watch Monday Morning

Futures Fall on Further Trade News and 4 Other Stories to Watch Monday Morning

60 Seconds: What is the Yield Curve and Why is Everyone Talking About It?

60 Seconds: What is the Yield Curve and Why is Everyone Talking About It?

Jim Cramer's Investing Rule #2: It's OK to Pay Taxes

Jim Cramer's Investing Rule #2: It's OK to Pay Taxes

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: Here Is Why Carvana Isn't Worried About Amazon

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech